Art

J-GLOBAL ID：202002291062878529   Reference number：20A1056604

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

NY-ESO-1を発現する難治性固形腫瘍患者におけるNOD2およびTLR9刺激剤によるNY-ESO-1蛋白質癌ワクチンの第1相臨床試験【JST・京大機械翻訳】

Author (20)： Ishihara Mikiya (Department of Medical Oncology, Mie University Hospital, Tsu, Mie, Japan) ,  Tono Yasutaka (Department of Medical Oncology, Mie University Hospital, Tsu, Mie, Japan) ,  Miyahara Yoshihiro (Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan) ,  Muraoka Daisuke (Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan) ,  Harada Naozumi (United Immunity, Co., Ltd., Room220, Mie University Campus Incubator, Tsu, Mie, Japan) ,  Kageyama Shinichi (Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan) ,  Sasaki Takeshi (Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan) ,  Hori Yasuhide (Kameyama Nephro-Urologic Clinic, Kameyama, Mie, Japan) ,  Soga Norihito (Department of Urology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan) ,  Uchida Katsunori (Department of Pathology, Mie University Graduate School of Medicine, Tsu, Mie, Japan) ,  Shiraishi Taizo (Department of Pathology, Mie University Graduate School of Medicine, Tsu, Mie, Japan) ,  Sato Eiichi (Department of Pathology, Institute of Medical Science (Medical Research Center), Tokyo Medical University, Tokyo, Japan) ,  Kanda Hideki (Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan) ,  Mizuno Toshiro (Department of Medical Oncology, Mie University Hospital, Tsu, Mie, Japan) ,  Webster Gill A. (Innate Immunotherapeutics, Melbourne, VIC, Australia) ,  Ikeda Hiroaki (Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan) ,  Katayama Naoyuki (Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Mie, Japan) ,  Sugimura Yoshiki (Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan) ,  Shiku Hiroshi (Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan) ,  Shiku Hiroshi (Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan)
Material： Cancer Immunology, Immunotherapy
Volume： 69  Issue： 4  Page： 663-675  Publication year： 2020 
JST Material Number： W4135A  ISSN： 1432-0851  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Abstract/Point： Abstract: Cholesteryl pullulan...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A1056604&from=J-GLOBAL&jstjournalNo=W4135A") }}

Thesaurus term： adjuvant ,  antigen ,  anorexia ,  *protein ,  human(primates) ,  immunological reaction ,  *clinical trial ,  complex(substance) ,  *tumor vaccine ,  combination therapy ,  vaccination ,  oligomerization ,  monoclonal antibody ,  *solid tumor
Semi thesaurus term： 有害事象 , 【Automatic Indexing@JST】

Author keywords (4)： Cancer vaccine ,  NY-ESO-1 antigen ,  NOD2 ,  TLR9

JST classification (2)： Tumors(=neoplasms)of digestive system  (GH04000D) ,  Clinical application of immunotherapeutic agents and blood preparations  (GW22020O)

Terms in the title (11)： NY-ESO-1 ,  発現 ,  固形腫瘍 ,  患者 ,  NOD2 ,  TLR9 ,  刺激剤 ,  蛋白質 ,  癌ワクチン ,  1相 ,  臨床試験